Adverse effects
irritability, headache
ADVERSE EVENTS, ADVERSE EFFECTS, ADVERSE EVENT
There were four adverse events reported in the AZD4017 group, comprising transient headache (three participants) and an elevated TSH (one participant) which normalised by day 14. There was one reported adverse event in the placebo group (irritability). No other adverse events were reported throughout the duration of the study, or in the 30 days after the final administration of AZD4017 or placebo. There were no serious adverse effects or discontinuations due to adverse effects in either group.